181 related articles for article (PubMed ID: 38632023)
21. Increasing New Delhi metallo-β-lactamase-positive Escherichia coli among carbapenem non-susceptible Enterobacteriaceae in Taiwan during 2016 to 2018.
Huang YS; Tsai WC; Li JJ; Chen PY; Wang JT; Chen YT; Chen FJ; Lauderdale TL; Chang SC
Sci Rep; 2021 Jan; 11(1):2609. PubMed ID: 33510280
[TBL] [Abstract][Full Text] [Related]
22. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
[TBL] [Abstract][Full Text] [Related]
23. Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Vagnone PS; Witwer M; Castanheira M; Johnson JR
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152073
[TBL] [Abstract][Full Text] [Related]
24. Successful containment of carbapenem-resistant Enterobacteriaceae by strict contact precautions without active surveillance.
Kim NH; Han WD; Song KH; Seo HK; Shin MJ; Kim TS; Park KU; Ahn S; Yoo JS; Kim ES; Kim HB
Am J Infect Control; 2014 Dec; 42(12):1270-3. PubMed ID: 25465255
[TBL] [Abstract][Full Text] [Related]
25. Risk factors associated with extended-spectrum β-lactamase-producing Enterobacteriaceae nosocomial bloodstream infections in a tertiary care hospital: a clinical and molecular analysis.
Muro S; Garza-González E; Camacho-Ortiz A; González GM; Llaca-Díaz JM; Bosques F; Rositas F
Chemotherapy; 2012; 58(3):217-24. PubMed ID: 22814216
[TBL] [Abstract][Full Text] [Related]
26. Antimicrobial susceptibilities of the ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales isolates causing intra-abdominal infections in the Asia-Pacific region during 2008-2014: Results from the Study for Monitoring the Antimicrobial Resistance Trends (SMART).
Jean SS; Hsueh PR;
J Glob Antimicrob Resist; 2020 Jun; 21():91-98. PubMed ID: 31627023
[TBL] [Abstract][Full Text] [Related]
27. The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance.
Ikenoue C; Matsui M; Inamine Y; Yoneoka D; Sugai M; Suzuki S;
BMC Infect Dis; 2024 Feb; 24(1):209. PubMed ID: 38360618
[TBL] [Abstract][Full Text] [Related]
28. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
Sader HS; Carvalhaes CG; Kimbrough JH; Mendes RE; Castanheira M
Int J Antimicrob Agents; 2024 Apr; 63(4):107113. PubMed ID: 38354826
[TBL] [Abstract][Full Text] [Related]
29. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
30. Emergence of extended-spectrum β-lactamase (ESBL) and/or carbapenemase producing Enterobacteriaceae (CPE) and their antimicrobial resistance.
Koren J; Hubenakova Z; Drahovska H; Ozaee E; Markuskova B; Lichvarikova A
Bratisl Lek Listy; 2019; 120(12):935-940. PubMed ID: 31855054
[TBL] [Abstract][Full Text] [Related]
31.
Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Sahm DF
J Med Microbiol; 2020 Feb; 69(2):207-217. PubMed ID: 31976856
[No Abstract] [Full Text] [Related]
32. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
Jean SS; Lee WS; Bai KJ; Yu KW; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):290-5. PubMed ID: 25600841
[TBL] [Abstract][Full Text] [Related]
33. An Increase in the clinical isolation of acquired AmpC β-lactamase-producing Klebsiella pneumoniae in Korea from 2007 to 2010.
Park MJ; Kim TK; Song W; Kim JS; Kim HS; Lee J
Ann Lab Med; 2013 Sep; 33(5):353-5. PubMed ID: 24003426
[TBL] [Abstract][Full Text] [Related]
34. Susceptibility of clinical isolates of meticillin-resistant Staphylococcus aureus and phenotypic non-extended-spectrum β-lactamase-producing Klebsiella pneumoniae to ceftaroline in Taiwan: Results from Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012-2018 and Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2018-2019.
Jean SS; Ko WC; Hsueh PR;
Int J Antimicrob Agents; 2020 Jul; 56(1):106016. PubMed ID: 32422316
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland.
Nordmann P; Bouvier M; Poirel L
Eur J Clin Microbiol Infect Dis; 2023 Sep; 42(9):1145-1152. PubMed ID: 37566365
[TBL] [Abstract][Full Text] [Related]
36. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).
Sader HS; Mendes RE; Duncan L; Kimbrough JH; Carvalhaes CG; Castanheira M
Diagn Microbiol Infect Dis; 2023 Jun; 106(2):115945. PubMed ID: 37060707
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates.
Maraki S; Mavromanolaki VE; Magkafouraki E; Moraitis P; Stafylaki D; Kasimati A; Scoulica E
Infection; 2022 Apr; 50(2):467-474. PubMed ID: 34854060
[TBL] [Abstract][Full Text] [Related]
38. [Investigation of Plasmid Mediated mcr Colistin Resistance Gene in Clinical Enterobacterales Isolates].
Özkaya E; Buruk CK; Tosun İ; Toraman B; Kaklıkkaya N; Aydın F
Mikrobiyol Bul; 2020 Apr; 54(2):191-202. PubMed ID: 32723275
[TBL] [Abstract][Full Text] [Related]
39. Molecular characteristics of carbapenemase-producing Enterobacterales in the Netherlands; results of the 2014-2018 national laboratory surveillance.
van der Zwaluw K; Witteveen S; Wielders L; van Santen M; Landman F; de Haan A; Schouls LM; Bosch T;
Clin Microbiol Infect; 2020 Oct; 26(10):1412.e7-1412.e12. PubMed ID: 32006688
[TBL] [Abstract][Full Text] [Related]
40. Emergence of NDM-producing Enterobacterales infections in companion animals from Argentina.
de Mendieta JM; Argüello A; Menocal MA; Rapoport M; Albornoz E; Más J; Corso A; Faccone D
BMC Vet Res; 2024 May; 20(1):174. PubMed ID: 38702700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
